INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY

INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY

This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an induc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HICKLIN, Daniel, ISAACS, Randi, SEIDEL-DUGAN, Cynthia, SALMERON-GARCIA, Jose Andres, BRODKIN, Heather, WINSTON, William
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an inducible IL-2 prodrug and an anti-PD-l antibody or antigen binding fragment thereof. A preferred anti-PD-l antibody is pembrolizumab. The inducible IL-2 prodrug can be Compound 1, Compound 2, Compound 3, or Compound 4. La présente invention concerne des procédés et des compositions pour le traitement du cancer à l'aide d'une polythérapie comprenant un promédicament IL-2 inductible en combinaison avec du pembrolizumab.